



Supplementary figure S1: Gender was prognostic for neuroblastoma patients. OS and EFS of 130 patients were estimated by Kaplan-Meier analysis within a 5-year period. (A) OS (log-rank test, $P > 0.05$) and (B) EFS (log-rank test, $P < 0.05$) of patient's dependent on gender.



Supplementary figure S2: (A) OS and (B) EFS of 130 patients in 5 years were calculated based on Age-groups by Kaplan-Meier method.



Supplementary figure S3: (A) OS and (B) EFS of 130 patients in 5 years were calculated based on the origin of a tumour by Kaplan-Meier method.

Supplementary table S1. Median for survival time.

	Median Survival Time (months)			
	OS time	p-value	EFS time	p-value
Gender				
Male	26.00 ± 2.697	0.046	29.00 ± 3.58	0.046
Female	26.00 ± 1.31		*	
INSS stage				
Stage I, II and IVs	*	0.000	*	0.000
Stage III and IV	24.00 ± 1.772		27.00 ± 1.322	
MYCN				
No	29.00 ± 1.82	0.000	*	0.000
Yes	18.00 ± 1.20		19.00 ± 2.96	

* survival exceeds 50% at the longest time point, then median survival cannot be computed

NB = neuroblastoma; INSS = International Neuroblastoma Staging System; OS = Overall Survival; EFS = Event-free survival; P-value less than 0.05 considered significant.

Supplementary table S2. Interaction of MYCN-status with clinical factors in the effect on outcome of patients with NB.

Variables	Interaction HR and 95%CI	Interaction p-value
Overall survival		
MYCN-amplification Gender (male)	2.140 (1.115 – 4.108)	0.022
MYCN-amplification Age (>18 months)	3.573 (1.973 - 6.469)	0.000
Event-free survival		
MYCN-amplification Gender (male)	2.199 (0.935 - 5.169)	0.071
MYCN-amplification Age (>18 months)	4.594 (1.635 – 12.912)	0.004

NB = neuroblastoma; P-value less than 0.05 considered significant.